Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT04017065
Other study ID # MAXFRAME
Secondary ID
Status Terminated
Phase
First received
Last updated
Start date October 1, 2020
Est. completion date June 11, 2021

Study information

Verified date August 2020
Source AO Innovation Translation Center
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

The aim of this international, prospective, multicenter case series (patient registry) is to gather the first evidence on the use of the MAXFRAME™ system in normal clinical settings during deformity correction of both, the upper and lower limb, and gain information on indications, the handling of the device from the patients' and surgeons' perspective, as well as number of re-planning needed. It is planned to prospectively follow up to 100 patients treated with the MAXFRAME™ system. Information on patients entered into the registry will be collected from before the surgery until the removal of the device.


Description:

The newly developed MAXFRAME™ system from DePuy Synthes® is a multi-Axial correction system based on the hexapod configuration. The indications for the MAXFRAME™ include, but are not limited to, the treatment of open or closed fractures of long bones, pseudarthrosis, limb lengthening via epiphyseal or metaphyseal distraction, joint arthrodesis, to bridge infected fractures or non-unions, to correct bony or soft tissue deformities, and to correct of segmental defects. One of the main novelties of this system is the Perspective Frame Matching (PFM) technique. This software system uses the post-operative x-rays with the entire frame mounted to the bone to generate a 3D visualization of the frame and the exact mounting parameters as well as a representation of the deformity with regards to the position within the frame. This system generates a treatment plan according to the exact representation of the frame, and the deformity at the starting point of the correction. The risk of a frame mal-positioning is reduced, which in return is believed to reduce the risk of a false correction and hopefully leads to a more precise result. Further, this reduces the need for adaptations to the initial treatment protocol, which require repeated radiological assessment and may alienate the patient during the whole process of the deformity correction. To the investigator's knowledge there are no published studies investigating the accuracy of this method, therefore the aim of the proposed prospective multicenter registry is to gather first evidence on the use of the MAXFRAME™ system in clinical settings and gain information on indications, handling, the number of re-planning's needed, and treatment related adverse events. Up to 100 patients treated with the MAXFRAME™ system are planned to be included for two years enrollment period. Each patient will be followed up from before the surgery until the removal of the device. All follow-up visits are according to standard of care. There are fixed time points (visits) during a normal deformity correction process and follow-up: - Baseline = pre-operative assessment - Surgery = application of the frame (defined as day 0) - Post-OP = post-operative image assessment (for PFM planning) - Frame removal (including conversion, if applicable) Further, there are additional time points (visits). An additional visit is defined as every consultation during the deformity correction process, until the frame is removed, when a registry specific event of interest occurs. The events of interest for additional visits are the following: - Re-plannings - Re-operation / surgical interventions - Changes to the frame - Treatment related adverse event - Deformity corrected Following data points will be collected pre-, intra- and post-operatively: Patients demographics, medical history and underlying diseases, Indication for the use of the MAXFRAMETM system, Treatment goal(s), Treatment planning, Surgical details, Changes in treatment plan, Frame removal, Radiological and calculated outcome assessment of the deformity correction and/or lengthening, Treatment-related Adverse Events, Experience with MAXFRAMETM system.


Recruitment information / eligibility

Status Terminated
Enrollment 100
Est. completion date June 11, 2021
Est. primary completion date June 11, 2021
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - Any patient undergoing surgical treatment (primary or revision) for deformity correction using the MAXFRAME™ system - Informed consent obtained, i.e.: - Ability to understand the content of the patient information/ICF - Willingness and ability to participate in the clinical investigation according to the Registry Plan (RP) - Signed and dated IRB/EC-approved written informed consent OR - Written consent provided according to defined and IRB/EC approved procedures for patients who are not able to provide independent written informed consent Exclusion Criteria: - Participation in any other medical device or medicinal product study within the previous month that could influence the treatment observed in this registry - Pregnancy - Intraoperative decision to use another device than MAXFRAMETM

Study Design


Intervention

Device:
DePuy Synthes MAXFRAMETM system
Patients treated with the MAXFRAMETM system will be followed up from before the surgery until the removal of the device. All treatments are based on individual clinician's judgement and the patient characteristics. The registry does not dictate any specific treatment.

Locations

Country Name City State
Switzerland University of Berne Children's Hospital Department of pediatric surgery Berne Schweiz
United States Penn State Hershey Bone and Joint Institute Hershey Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
AO Innovation Translation Center

Countries where clinical trial is conducted

United States,  Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Baseline characteristics Demographics, medical history baseline until the removal of the device (standard approximately 6 months)
Primary Type of surgery primary or revision surgery Day of surgery until removal of the device (standard approximately 6 months)
Primary Bone lengthening measurement Bone lengthening (in mm) baseline until the removal of the device (standard approximately 6 months)
Primary Varus or valgus correction assessment Varus or valgus correction (in degrees) baseline until the removal of the device (standard approximately 6 months)
Primary Rotational correction assessment Rotational correction (in degrees) baseline until the removal of the device (standard approximately 6 months)
Primary Ante- or retro-curvature correction assessment Ante- or retro-curvature correction (in degrees) baseline until the removal of the device (standard approximately 6 months)
Primary Bone union / fusion assessment Bone union / fusion (in the case of an arthrodesis) removal of the device (standard approximately 6 months)
Primary Radiological assessments Radiological assessment according to the measured anatomical angles (degree) baseline until the removal of the device (standard approximately 6 months)
Primary Radiological assessments of deformity parameters deformity parameters depending on the level of the deformity (degree) baseline until the removal of the device (standard approximately 6 months)
Primary Reason for changes of treatment plan reason for any treatment plan changes baseline until the removal of the device (standard approximately 6 months)
Primary End of deformity correction Length gained (real (mm) according to the lengthened bone) baseline until the removal of the device (standard approximately 6 months)
Primary Assessment of the surgeon and patients experience with the MAXFRAME™ system Survey with four questions to rate via numeric rating scale (0= not satisfied at all ; 10= totally satisfied) removal of the device (standard approximately 6 months)
See also
  Status Clinical Trial Phase
Terminated NCT02161016 - A Clinical Study of Outcomes in Foot and Ankle Bone Grafting Using map3® Cellular Allogeneic Bone Graft Phase 4